Study backs gene therapy for heart failure:
This article was originally published in Clinica
Executive Summary
Collateral Therapeutics' angiogenesis-promoting gene has shown promise as a non-surgical treatment for heart failure, according to results from a placebo-controlled animal study in the March issue of Cardiac and Vascular Regeneration. Intracoronary delivery of the company's human gene fibroblast growth factor-4 (FGF-4) increased heart function and reduced the size of dilated hearts over the three-week study period. The San Diego, California-based company has licensed the gene exclusively from New York University. Collateral is also using the FGF-4 gene to develop a treatment for coronary artery disease.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.